Cytokinetics Inc is a late-stage biopharmaceutical company based in South San Francisco, California, focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as treatments for diseases in which muscle performance is compromised. Its pipeline targets cardiovascular and neuromuscular conditions, including hypertrophic cardiomyopathy, heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. Aficamten, a cardiac myosin inhibitor, is its lead cardiovascular candidate for hypertrophic cardiomyopathy; omecamtiv mecarbil is a cardiac myosin activator; and reldesemtiv and other skeletal muscle activators target neuromuscular disorders. The company conducts clinical trials in the United States and internationally, often in collaboration with partners and academic centers. It has no significant marketed products and generates revenue primarily through research collaborations, licensing agreements, and milestone payments rather than product sales, while funding operations largely through equity financings and partnership proceeds.

Piotroski F-Score

Insider Sell